Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812955 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 474
- Enrollment target
NCT00812955 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 474 participants.
The verdict
NCT00812955, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 474 participants
- Enrollment target
Study Summary
The primary purpose of this study is to test the effect and safety of three different doses of ABT-143 compared to simvastatin in subjects with elevated levels of low density lipoprotein cholesterol ("bad cholesterol") and triglycerides.
Interventions
- DRUG simvastatin
- DRUG ABT-143
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00812955
The ClinicalTrials.gov registry entry for NCT00812955 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which simvastatin is the first listed.
NCT00812955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00812955 about?
NCT00812955 is a clinical study titled "Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides". The primary purpose of this study is to test the effect and safety of three different doses of ABT-143 compared to simvastatin in subjects with elevated levels of low density lipoprotein cholesterol ("bad cholesterol") and triglycerides.
What is the current status of trial NCT00812955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 474 participants. The study started on 2008-11. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00812955?
The interventions under investigation include: simvastatin (DRUG), ABT-143 (DRUG).
Who is sponsoring clinical trial NCT00812955?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.